Allogene Therapeutics, Inc. officer Geoffrey M. Parker filed a Form 144 notice on October 21, 2026, proposing the sale of 36,342 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed seller: Geoffrey M. Parker, identified as an officer of Allogene Therapeutics, Inc.
  • Shares proposed for sale: 36,342 shares of common stock, with an aggregate market value of $48,698.28.
  • Source of shares: 100,000 shares acquired on October 20, 2026, through the vesting of a restricted stock unit award granted as part of the issuer's equity compensation plan.
  • Approximate date of sale: October 21, 2026, on the NASDAQ exchange.
  • Shares outstanding: 345,490,881 shares of common stock, according to the filing.
  • Prior sales: No securities of the issuer were sold by the filer in the past three months, per the filing.

Parker's Proposed Rule 144 Sale Following RSU Vesting at Allogene Therapeutics

According to the Form 144 filed with the U.S. Securities and Exchange Commission on October 21, 2026, Geoffrey M. Parker, an officer of Allogene Therapeutics, Inc. (NASDAQ:ALLO), proposed to sell 36,342 shares of the company's common stock. The filing lists the aggregate market value of the proposed sale at $48,698.28. The broker named in the notice is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY 10004.

The filing discloses that the shares proposed for sale were drawn from a block of 100,000 shares acquired on October 20, 2026, through the vesting of a restricted stock unit award. The nature of payment is described as "Granted as part of issuer equity compensation plan," with the acquiring party listed as Allogene Therapeutics, Inc. The date of payment is also noted as October 20, 2026.

Parker certified in the notice, as required by the form, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The filing reports no sales of Allogene securities by Parker in the three months prior to the notice date. The total shares of common stock outstanding at the time of the filing were listed as 345,490,881.

What Was Disclosed

A Form 144 notice filed by Allogene Therapeutics officer Geoffrey M. Parker on October 21, 2026, proposed the sale of 36,342 shares of common stock, valued at $48,698.28, following the vesting of a restricted stock unit award on October 20, 2026.